## UNITED STATES SECURITIES AND EXCHANGE COMMISSION JUNE 20, 2018

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

Xeris Pharmaceuticals, Inc.

File No. 333-225191 - CF#36267

Xeris Pharmaceuticals, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the exhibits to a Form S-1 registration statement filed on May 24, 2018, as amended.

Based on representations by Xeris Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time period specified:

Exhibit 10.12	through May 1, 2028
Exhibit 10.13	through May 1, 2028
Exhibit 10.14	through May 1, 2028
Exhibit 10.15	through May 1, 2028
Exhibit 10.17	through May 1, 2028

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary